ASKA Pharmaceutical Holdings Co.,Ltd.

TSE:4886.T

2145 (JPY) • At close September 13, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

202320222021202020192018201720162015201420132012
Revenue 62,84360,46156,60755,18152,54246,70548,94448,52743,21542,90739,50140,963
Cost of Revenue 32,17831,87630,25529,79828,52527,81430,05929,61426,07225,71422,43123,054
Gross Profit 30,66528,58526,35225,38324,01718,89118,88518,91317,14317,19317,07017,909
Gross Profit Ratio 0.4880.4730.4660.460.4570.4040.3860.390.3970.4010.4320.437
Reseach & Development Expenses 4,7284,2273,59804,9134,4934,0554,9704,1744,0254,1444,269
General & Administrative Expenses 13,13113,16112,191011,60311,72911,04211,13610,78310,69211,11111,323
Selling & Marketing Expenses 6,3056,0885,76705,9938859631,0131,0211,0501,0981,255
SG&A 19,43619,24917,95821,77317,59612,61412,00512,14911,80411,74212,20912,578
Other Expenses -165-67-73000001000
Operating Expenses 24,16423,47621,55621,77322,50917,10716,06017,11915,97715,65516,27516,424
Operating Income 6,5015,1084,7953,6101,5081,7842,8251,7941,1661,4117021,047
Operating Income Ratio 0.1030.0840.0850.0650.0290.0380.0580.0370.0270.0330.0180.026
Total Other Income Expenses Net 3,3612471,368-35-607992381,506282277244545
Income Before Tax 9,8625,3576,1633,5759011,8833,0633,3001,4481,6889461,592
Income Before Tax Ratio 0.1570.0890.1090.0650.0170.040.0630.0680.0340.0390.0240.039
Income Tax Expense 2,3161,1181,873861252138674356747530421482
Net Income 7,5454,2384,2902,7136491,7442,3882,9447011,1934951,114
Net Income Ratio 0.120.070.0760.0490.0120.0370.0490.0610.0160.0280.0130.027
EPS 266.49150.08151.2295.6322.9461.884.77105.3725.1442.8617.8240.27
EPS Diluted 266.49150.08151.2295.6322.9461.884.77105.3725.1442.8617.8240.27
EBITDA 9,1638,4627,8636,9725,2694,4025,2194,2953,2233,2263,1613,481
EBITDA Ratio 0.1460.140.1390.1260.10.0940.1070.0890.0750.0750.080.085